When are combinations of antibiotics clinically useful?

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Antimicrobial resistance (AMR) poses a significant global health threat.
• Antibacterial combination therapy is explored as a strategy to mitigate AMR development.
• Potential benefits include synergy, broader coverage, and immune modulation.

Purpose of the Study:

• To review the evidence for antibacterial combination therapy in various clinical scenarios.
• To assess the impact of combination therapy on antimicrobial resistance.
• To identify specific conditions where combination therapy is advantageous or potentially harmful.

Main Methods:

• Review of current research literature and global standards of clinical care.
• Analysis of clinical scenarios where combination therapy is currently employed or recommended.
• Evaluation of evidence regarding resistance development and treatment outcomes.

Main Results:

• Combination therapy is beneficial in severe community-acquired pneumonia, severe hospital-acquired/ventilator-associated pneumonia (especially with high resistance risk), multi-drug resistant Gram-negative infections, and severe group A streptococcal infections.
• Outside of tuberculosis, combination therapy's benefit in improving outcomes is limited to specific circumstances.
• Little evidence supports combination therapy's role in preventing bacterial resistance development.

Conclusions:

• Antibacterial combination therapy is a valuable tool in select severe infections and for managing resistant pathogens.
• Its routine use outside of specific indications, particularly for preventing resistance, is not supported by current evidence.
• High-quality research is crucial to further define the role and impact of combination antibacterial therapy.